Historical Valuation
Generation Bio Inc (GBIO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 63.81 is considered Overvalued compared with the five-year average of -3.84. The fair price of Generation Bio Inc (GBIO) is between 0.35 to 3.71 according to relative valuation methord. Compared to the current price of 5.48 USD , Generation Bio Inc is Overvalued By 47.82%.
Relative Value
Fair Zone
0.35-3.71
Current Price：5.48
47.82%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Generation Bio Inc (GBIO) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.92 , the current P/B ratio is approximately -21.34% higher. Relative to its 5-year average P/B ratio of 1.48, the current P/B ratio is about -50.96% higher. Generation Bio Inc (GBIO) has a Forward Free Cash Flow (FCF) yield of approximately -312.70%. Compared to its 3-year average FCF yield of -125.06%, the current FCF yield is approximately 150.05% lower. Relative to its 5-year average FCF yield of -82.31% , the current FCF yield is about 279.92% lower.
P/B
Median3y
0.92
Median5y
1.48
FCF Yield
Median3y
-125.06
Median5y
-82.31
Competitors Valuation Multiple
AI Analysis for GBIO
The average P/S ratio for GBIO competitors is 11.85, providing a benchmark for relative valuation. Generation Bio Inc Corp (GBIO.O) exhibits a P/S ratio of 63.81, which is 438.63% above the industry average. Given its robust revenue growth of -78.90%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for GBIO
1Y
3Y
5Y
Market capitalization of GBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GBIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GBIO currently overvalued or undervalued?
Generation Bio Inc (GBIO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 63.81 is considered Overvalued compared with the five-year average of -3.84. The fair price of Generation Bio Inc (GBIO) is between 0.35 to 3.71 according to relative valuation methord. Compared to the current price of 5.48 USD , Generation Bio Inc is Overvalued By 47.82% .
What is Generation Bio Inc (GBIO) fair value?
GBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Generation Bio Inc (GBIO) is between 0.35 to 3.71 according to relative valuation methord.
How does GBIO's valuation metrics compare to the industry average?
The average P/S ratio for GBIO's competitors is 11.85, providing a benchmark for relative valuation. Generation Bio Inc Corp (GBIO) exhibits a P/S ratio of 63.81, which is 438.63% above the industry average. Given its robust revenue growth of -78.90%, this premium appears unsustainable.
What is the current P/B ratio for Generation Bio Inc (GBIO) as of Jan 11 2026?
As of Jan 11 2026, Generation Bio Inc (GBIO) has a P/B ratio of 0.73. This indicates that the market values GBIO at 0.73 times its book value.
What is the current FCF Yield for Generation Bio Inc (GBIO) as of Jan 11 2026?
As of Jan 11 2026, Generation Bio Inc (GBIO) has a FCF Yield of -312.70%. This means that for every dollar of Generation Bio Inc’s market capitalization, the company generates -312.70 cents in free cash flow.
What is the current Forward P/E ratio for Generation Bio Inc (GBIO) as of Jan 11 2026?
As of Jan 11 2026, Generation Bio Inc (GBIO) has a Forward P/E ratio of -0.39. This means the market is willing to pay $-0.39 for every dollar of Generation Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Generation Bio Inc (GBIO) as of Jan 11 2026?
As of Jan 11 2026, Generation Bio Inc (GBIO) has a Forward P/S ratio of 63.81. This means the market is valuing GBIO at $63.81 for every dollar of expected revenue over the next 12 months.